Inflammation and Erythropoietin Resistance in Chronic Kidney Disease: A Cross‐Sectional Study of C‐Reactive Protein and Anemia in Hemodialysis Patients
Journal of Clinical Laboratory Analysis · 2026-05 · 40 (10)
DOI: 10.1002/jcla.70247 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Laboratory Analysis, online erschienen am 02.05.2026. Verfasst von Collince Odiwuor Ogolla und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Applied Health Science, School of Health Science, Kisii University, Kisii, Kenya. Hauptthemen laut MEDLINE: C-Reactive Protein, Erythropoietin, Anemia, Renal Dialysis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Anemia represents a frequent complication in patients with chronic kidney disease (CKD) on hemodialysis. Inflammation results in disruption of erythropoiesis and establishment of less effective responses to erythropoiesis‐stimulating agents (ESAs).
Objective
This study investigated how systemic inflammation, which C‐reactive protein (CRP) measured, relates to anemia severity and erythropoietin (EPO) responsiveness among patients with chronic kidney disease who undergo maintenance hemodialysis.
Methods
Cross‐sectional study design involving 120 CKD patients. Participants were classified into high inflammation group for CRP levels at or above 10 mg/L and low inflammation group for CRP levels below 10 mg/L. Hematological parameters and iron status indices were analyzed, and weekly EPO doses were recorded. Pearson correlation and multivariable linear regression analyses were done while controlling for age, sex, comorbidities, and dialysis duration.
Results
High inflammation group displayed hematocrit level of 29.6% ± 4.8% while the control group showed a level of 34.2% ± 5.2% which produced a statistically significant difference ( p < 0.001). CRP exhibited a negative correlation with hematocrit ( r = −0.42, p < 0.001) and transferrin saturation ( r = −0.36, p < 0.001) but showed a positive correlation with EPO dose ( r = 0.48, p < 0.001). CRP established an independent relationship with hematocrit ( β = −0.43, 95% CI: −0.58 to −0.28) and EPO dosage ( β = 401, 95% CI: 210 to 592) during the multivariable analysis.
Limitations
Cross‐sectional design restricts causal relationships while the research team evaluated CRP as the only inflammatory marker.
Conclusions
Systemic inflammation establishes a significant connection to anemia severity and EPO resistance, which affects CKD patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Applied Health Science, School of Health Science, Kisii University, Kisii, Kenya.
- Department of Medical Laboratory Science, School of Health Science, South Eastern Kenya University, Kitui, Kenya.
- Department of Medical Laboratory Science, School of Health Science, Kisii University, Kisii, Kenya.
ORCID-Profile: Collince Odiwuor Ogolla, Lucy W Karani
Zitieren
APA
Ogolla, C. O., Karani, L. W., Musyoki, S., & Maruti, P. (2026). Inflammation and Erythropoietin Resistance in Chronic Kidney Disease: A Cross‐Sectional Study of C‐Reactive Protein and Anemia in Hemodialysis Patients. Journal of Clinical Laboratory Analysis, 40(10). https://doi.org/10.1002/jcla.70247
Vancouver
Ogolla CO, Karani LW, Musyoki S, Maruti P. Inflammation and Erythropoietin Resistance in Chronic Kidney Disease: A Cross‐Sectional Study of C‐Reactive Protein and Anemia in Hemodialysis Patients. Journal of Clinical Laboratory Analysis. 2026;40(10). doi:10.1002/jcla.70247
BibTeX
@article{Ogolla2026,
author = {Ogolla, Collince Odiwuor and Karani, Lucy W and Musyoki, Stanslaus and Maruti, Phidelis},
title = {Inflammation and Erythropoietin Resistance in Chronic Kidney Disease: A Cross‐Sectional Study of C‐Reactive Protein and Anemia in Hemodialysis Patients},
journal = {Journal of Clinical Laboratory Analysis},
year = {2026},
volume = {40},
number = {10},
doi = {10.1002/jcla.70247}
}
EUVIMED